Vir Biotechnology vs Xencor
VIR and XNCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How VIR and XNCR compare
Xencor is the larger company, worth 1.6 times as much as Vir Biotechnology ($2.6B against $1.6B).
Vir Biotechnology grew revenue faster over the last twelve months (1496% versus −28.6% for Xencor).
Vir Biotechnology keeps more of each dollar of sales as profit, with a net margin of −83.0% compared with −156% at Xencor.
Vir Biotechnology scores higher on the StockData Score (11 against 5 for Xencor), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | VIR | XNCR |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $2.6B |
| Share price | $9.25 | $34.50 |
| Change, 1 year | 64.3% | 131% |
| Change, 5 years | −74.3% | −2.7% |
| Beta (5Y) | 0.80 | −0.05 |
| Employees | 367 | 260 |
| StockData Score | ||
| Total score | 11 (better) | 5 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.2× (better) | 24.4× |
| P/B | 1.6× (better) | 5.1× |
| FCF yield | −13.0% | −8.1% (better) |
| Fair value | $13.31 | $11.73 |
| Margin of safety | 30.5% (better) | −194% |
| Growth | ||
| Revenue growth (TTM) | 1496% (better) | −28.6% |
| Revenue growth, 5Y average | −2.1% | 0.47% (better) |
| Profitability | ||
| Operating margin | −92.4% (better) | −206% |
| Net margin | −83.0% (better) | −156% |
| FCF margin | −67.1% (better) | −198% |
| Return on equity | −26.1% (better) | −29.1% |
| Return on invested capital | −55.2% | −26.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.21 (better) |
| Interest coverage | – | −8.0× |
| Current ratio | 6.04 | 6.39 (better) |
| Altman Z-score | 2.57 | 5.01 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 86.6% | 113% |
| Held by insiders | 17.1% | 1.6% |
| Insider net buying, 12 months | −$4.0M (better) | −$7.5M |
| Short interest, % of float | 12.0% | 17.6% |
Go deeper
- VIR stock overview
- VIR income statement
- VIR valuation and score
- XNCR stock overview
- XNCR income statement
- XNCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.